SABCS 2022

Part 1: Encouraging data that supports treatment decisions, but better focus on racial and social disparities is needed

Part 3: Testing for TROP-2 not needed / no prognostic factor found

Part 2: Treamtent options in high-risk breast cancer

Practice Changing ADC data confirmed

New treatment perspectives in luminal breast cancer

SERDs - who benefits? ESR1 testing required?

New insights: Are CTCs predictive or not?

New evidence regarding the chance of pregnancies in EBC

ADC: Do we need a target? Do we need a predicitve marker?

monarchE confirms increasing benefit. What are the real life implications?

RIGHT choice against Chemotherapy for aggressive disesase

Abemaciclib as standard of in high-risk HR+ HER2- primary BC

Adjuvant TH confirms excellent logn-term follow-up

Chemo without benefit in node-negative disease

Time to reconsider Ki-67 threshold?!

First trial about pregnancy in premenopausal early BC patients during their endocrinee adjuvant therapy

Platin-based neoadjuvant therapy in early TNBC: impact in pCR and prognosis in younger patients

Benefit of extended adjuvant treatment with endocrine therapy based on genomic profiling with Mammaprint

Interruption of endocrine therapy in case of desire to have children

T-DXd as (neo)adjuvant treatment HR+/HER2- patients

monarchE confirms data once more.

POSITIVE-Trial shwos that temporal therapy interruption is safe and allows pregnancy

Good news for young patients

Neoadyuvancia con carboplatino en cáncer de mama precoz y fenotipo triple negativo: impacto en RCp y pronóstico en mujeres jóvenes

POSITIVE-Trial dimostra che l'interruzione temporanea della terapia endocrina adiuvante è sicura e consente la gravidanza

El primer estudio sobre la gestación en pacientes con cáncer de mama precoz premenopaúsicas durante el tratamiento endocrino adyuvante

T-DXd as (neo)adjuvant treatment HR+/HER2- patients

Beneficio del tratamiento hormonal extendido según resultados de expresión génica con el test Mammaprint

Targeted approach for endocrine responsive visceral disease

Highlights on oral SERDS in HR+ mBC

Progress in research and clinic

A shift from chemotherapy to CDK4/6

SERENA-2 showed better PFS by camizestrant compared with fulvestrand

Il miglior approccio per la malattia endocrino-responsiva con malattia viscerale

SERENA-2 ha mostrato una migliore PFS grazie a camizestrant rispetto a fulvestrant

Highlights on oral SERDS in HR+ mBC

Endocrine combination despite visceral crisis

HR+/HER2-: Who still needs chemotherapy?

De-escalation in triple positive MammaCa

Continuing Palbociclib beyond progression does not improve PFS

RIB + ET appears to be the better option than chemotherapy in the 1stLine even in patients with aggressive HR+/HER2- BC

CDK4/6 inhibitors - a preferred option also for the highest risk patients

Treatment alternatives to chemotherapy for visceral crisis

Ribociclib + endocrine in high risk HR+/HER2- MBC superior to chemo

Inhibitory CDK4/6 opcją z wyboru również u chorych najwyższego ryzyka

T-Dxd keeps us excited

Great data - as usual with T-Dxd

Chemotherapy-free (neo)adjuvant treatment seems feasible for HR+/HER2- patients with T-DXd

Positive data for ER+ and HER2+ breast cancer

TDXd is the prefered option for pts previously treated with T-DM1

T-Dxd - ready for prime time in the 2nd line

Important OS update for T-DXd

T-DXd as therapy of choice even after T-DM1 in HER2+ mBC

Optimal side effect management required

T-DXd new standard after pretreatment with trastuzumab and a taxane in HER2+ mBC

Robust benefit of T-Dxd confirmed with new data

Clinically relevant and statistically significant benefit in OS and PFS with T-DXd

T-DXd with so far unkown efficacy

Positive data for ER+ and HER2+ breast cancer

TDXd es la primera opción para pacientes tratados previamente con T-DM1

Importante actualisation des données de survie globale pour le T-DXd

Beneficio clínicamente y estadísticamente significativo en OS y PFS con T-DXd

T-DXd – skuteczność, jakiej dotąd nie znaliśmy

oral SERDs on the rise?

Oral SERDs are superior

Positive data for ER+ and HER2+ breast cancer

A new drug in the endocrine landscape

Une nouvelle molécule dans le traitement hormonal du cancer du sein

Una nouva molecola nel trattamento ormonale del tumore al seno

Positive data for ER+ and HER2+ breast cancer

Her2-low discordance rate at 40%

Positive data for ER+ and HER2+ breast cancer

Capivasertib - A drug for allcomers

Pregnancies after primary breast cancer

Estradiol withdrawal affects the micromillieu in the brain

Triple-positive MBC does not require chemotherapy.

Olaparib as an alternative to carboplatin in aggressive HR+/HER2- mBC?

AKT inhibitor capivasertib in HR+ mBC

Promising new player in the second line setting in advanced luminal BC

ADC or other therapies after CDK4/6

CTC count may help in therapy decisions

CTCs with metastatic breast cancer re-visited

Le compte des CTC peut orienter la décision thérapeutique

Positive data for ER+ and HER2+ breast cancer

Obiecująca nowa opcja w drugiej linii zaawansowanego, luminalnego raka piersi

Capivasertib un nuovo standard per tutti?

HER2+ - no new approval but long-term follow up data confirm established therapies

TNBC - Practice changing data lead to new approvals - and more to come!

HR+ - Practice changing data - which therapy for which patients?

The Right Choices? CDK4/6i vs. Chemo, SERDs & ESR1?

New Indications: ADCs & HER2-low

Dealing with Brain mets / Update TNBC